With Additional Active Ingredient Patents (Class 514/223.5)
-
Publication number: 20100028429Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: July 31, 2009Publication date: February 4, 2010Inventors: Neil M. Cowen, Khaled A. Yamout
-
Publication number: 20100003321Abstract: Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.Type: ApplicationFiled: June 26, 2007Publication date: January 7, 2010Inventors: Yu Cao, Yatindra Joshi, Ping Li, Madhusudhan Pudipeddi, Alan E. Royce, Robert F. Wagner, Jiahao Zhu
-
Publication number: 20090312311Abstract: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseasesType: ApplicationFiled: April 4, 2007Publication date: December 17, 2009Inventors: Gary Michael Ksander, Suraj Shivappa Shetty
-
Publication number: 20090221549Abstract: A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.Type: ApplicationFiled: February 16, 2007Publication date: September 3, 2009Applicant: Gilead Colorado, Inc.Inventors: Michael J. Gerber, Richard J. Gorczynski, Robert L. Roden
-
Publication number: 20090215755Abstract: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidemias and of diseases related to dyslipidemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and hepatic diseases.Type: ApplicationFiled: May 11, 2009Publication date: August 27, 2009Applicant: SANOFI-AVENTISInventors: Michele Arnone, Jean Marc Herbert, Hassan Massoud Heshmati, Philip Janiak, Mohammed Bensaid
-
Publication number: 20090208583Abstract: Composition in the form of a tablet, comprising candesartan cilexetil and optionally further active agents and usual adjuncts, wherein the surface of at least the active agent candesartan cilexetil in this composition is provided with a coating, made from a compound or a mixture of compounds selected from tri-(C1-C6)alkyl citrate, di-(C1-C6)alkyl phthalate, di-(C1-C6)alkyl sebacate and polydimethysiloxanes and methods for production thereof.Type: ApplicationFiled: June 14, 2007Publication date: August 20, 2009Applicant: Siegfried Generics International AGInventors: Tillmann Rohrich, Waltraud Bueb, Enno Schweinberger
-
Publication number: 20090208573Abstract: New form of irbesartan having favourable chargeability is prepared from the alcoholic/etheric or ketonic solution of irbesartan after slow cooling with sporadic or light agitation and alternatively new crystalline form of an acid addition salt of irbesartan is prepared from the aqueous solution of a sodium salt of irbesartan after strongly acidifying aforesaid solution and subsequently adjusting pH with an alkali. Those are used in manufacturing a pharmaceutical composition.Type: ApplicationFiled: November 9, 2005Publication date: August 20, 2009Applicant: LEK PHARMACEUTICALS D.DInventor: Ljubomir Antoncic
-
Publication number: 20090202636Abstract: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.Type: ApplicationFiled: June 14, 2007Publication date: August 13, 2009Applicant: LEK Pharmaceuticals d.d.Inventors: Adnan Beso, Igor Legen, Sebastjan Reven
-
Publication number: 20090203679Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations of these.Type: ApplicationFiled: June 21, 2007Publication date: August 13, 2009Inventor: Matthias Willmann
-
Publication number: 20090156585Abstract: A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.Type: ApplicationFiled: November 8, 2006Publication date: June 18, 2009Inventors: Lili Feng, Sven Erik Godtfredsen, Bin Hu, Yugang Liu, Piotr Karpinski, Paul Allen Sutton, Mahavir Prashad, Michael J. Girgis, Thomas J. Blacklock
-
Publication number: 20090148526Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: February 24, 2009Publication date: June 11, 2009Inventors: Neil M. Cowen, Kenneth B. Kashkin, Khaled A. Yamout
-
Publication number: 20090149451Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.Type: ApplicationFiled: February 9, 2009Publication date: June 11, 2009Inventor: Neil M. Cowen
-
Publication number: 20090143335Abstract: The present invention relates to a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 and/or one or more inhibitors of OAT. The present invention further relates to a pharmaceutical composition comprising from about 0.5 mg to about 50 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the composition provides an in vivo plasma profile comprising a mean Tmax which is longer than about 20 minutes.Type: ApplicationFiled: October 17, 2008Publication date: June 4, 2009Applicant: H. LUNDBECK A/SInventors: Mie Larsen, Carsten Uhd Nielsen, Birger Brodin Larsen, Rene Holm
-
Publication number: 20090036432Abstract: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt thereof, and (ii) the diuretic amiloride or triameterine or a pharmaceutically acceptable salt thereof, and (iii) a further diuretic or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 26, 2008Publication date: February 5, 2009Applicant: Novartis AGInventor: Daniel Lucius Vasella
-
Publication number: 20090023714Abstract: The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low-dose loop diuretic and which are particularly useful for treating hypertension and heart failure. It is not only the overall natriuretic/diuretic effects which are increased due to said combination of thiazide diuretic and loop diuretic, but the undesired secondary effects regarding potassium and magnesium losses are significantly reduced as well. As a result, the desired hypocalciuric effect of the thiazide is maintained despite the presence of the loop diuretic.Type: ApplicationFiled: August 29, 2006Publication date: January 22, 2009Inventors: Heinrich Knauf, Ernst Mutschler
-
Publication number: 20080300227Abstract: The invention is directed to a drug for treating hypertension combined with serum hyperuricemia and/or hypercholesterolemia, with the active ingredients being 2-propyl-3-{[21-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-5,6,7, 8-tetrahydrocyclohepta imidazole-4-(3H)-one and a prodrug or salt thereof. Pratosartan can be used in combination with one or more diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene, amiloride, spironolactone, potassium canrenoate and traxanox sodium. Also, pratosartan can be used in combination with one or more hypolipidemic drugs chosen from statins, fibrates, cholesterol absorption inhibitors, cholesterol sequestrants and cholesterol excretion enhancers.Type: ApplicationFiled: August 1, 2008Publication date: December 4, 2008Inventors: Akira Tomiyama, Hiroshi Tomiyama, Hidetoshi Miyamoto, Keiichoro Hayashi, Seiichiro Mochizuki
-
Publication number: 20080292588Abstract: The invention is directed to 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.Type: ApplicationFiled: May 16, 2008Publication date: November 27, 2008Applicant: Anadys Pharmaceuticals, Inc.Inventors: Yuefen Zhou, Thomas Bertolini, Liansheng Li
-
Publication number: 20080275032Abstract: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.Type: ApplicationFiled: September 11, 2007Publication date: November 6, 2008Inventors: Yuefen Zhou, Liansheng Li, Stephen E. Webber, Peter Dragovich, Douglas E. Murphy, Chinh V. Tran, Jingjing Zhao, Frank Ruebsam
-
Publication number: 20080261959Abstract: This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and in this connection, to the amorphous form of valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of valsartan.Type: ApplicationFiled: November 21, 2007Publication date: October 23, 2008Inventors: Ashok Kumar, Manmohan Madhavrao Nimbalkar, Priti Jayesh Bhayani, Mukesh Subhodh Jha, Vaibhav Chinubhai Doshi
-
Publication number: 20080255101Abstract: The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia.Type: ApplicationFiled: June 10, 2008Publication date: October 16, 2008Applicant: NITROMED, INC.Inventors: David S. GARVEY, L. Gordon LETTS, Richard A. EARL, Maiko EZAWA, Xinqin FANG, Ricky D. GASTON, Subhash P. KHANAPURE, Chia-En LIN, Ramani R. RANATUNGE, Cheri A. STEVENSON, Shiow-Jyi WEY
-
Publication number: 20080227774Abstract: The invention is directed to 5,5-disubstituted-indolizinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.Type: ApplicationFiled: March 14, 2008Publication date: September 18, 2008Inventors: Frank Ruebsam, Peter Dragovich
-
Publication number: 20080214529Abstract: The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.Type: ApplicationFiled: December 12, 2007Publication date: September 4, 2008Inventors: Frank Ruebsam, Zhongxiang Sun, Benjamin Ayida, Yuefen Zhou, Alan X. Xiang
-
Publication number: 20080161296Abstract: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.Type: ApplicationFiled: November 15, 2005Publication date: July 3, 2008Inventors: Eric Davis, John P. O'Donnell, Peter Bruce Bottini, Andrew Shaw, R. Preston Mason
-
Publication number: 20080118564Abstract: New composition of candesartan cilexetil is prepared using up to 20% of carrageenan which suitably stabilized the active ingredient against degradation during the tableting.Type: ApplicationFiled: January 24, 2006Publication date: May 22, 2008Applicant: LEK PHARMACEUTICALS D.DInventors: Zdenka Jerala-Strukelj, Igor Legen
-
Publication number: 20080008751Abstract: The present invention provides stable pharmaceutical compositions comprising a combination of active pharmaceutical ingredients. The pharmaceutical composition of the present invention comprises a moisture sensitive drug, in particular an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril, as an active ingredient, a second pharmaceutically active ingredient such as for example Hydrochlorothiazide, and at least one pharmaceutical excipient, wherein the moisture sensitive active pharmaceutical ingredient is wet granulated with a solution of at least one pharmaceutical excipient, and methods for preparing such stable pharmaceutical compositions.Type: ApplicationFiled: July 10, 2006Publication date: January 10, 2008Inventor: Michael Fox
-
Publication number: 20070244101Abstract: The subject invention relates to a composition and method for treating a patient employing co-formulation or co-administration of a thiazolidinedione (TZD) and a diuretic.Type: ApplicationFiled: April 17, 2007Publication date: October 18, 2007Inventor: Lawrence Solomon
-
Publication number: 20070196510Abstract: A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.Type: ApplicationFiled: August 24, 2006Publication date: August 23, 2007Inventors: Michael J. Gerber, Richard J. Gorczynski, Robert L. Roden
-
Patent number: 6878703Abstract: A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.Type: GrantFiled: May 20, 2003Date of Patent: April 12, 2005Assignee: Sankyo Company, LimitedInventors: Toshio Sada, Makoto Mizuno
-
Patent number: 6858228Abstract: The present invention is concerned with solid oral dosage forms of comprising a) an active agent selected from valsartan and optionally HCTZ, and b) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.Type: GrantFiled: September 20, 2002Date of Patent: February 22, 2005Assignee: Novartis AGInventors: Yoshimitsu Katakuse, Manfred Kohlmeyer, Takashi Taike, Robert Frank Wagner, Fujiki Yamato
-
Publication number: 20040254176Abstract: The present invention relates to a method of treatment of a condition or disease selected from the group consisting of hypertension, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, endothelial dysfunction, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke,Type: ApplicationFiled: July 27, 2004Publication date: December 16, 2004Inventors: Melissa Lynn Grigorieff, Suraj Shivappa Shetty, Randy Lee Webb
-
Publication number: 20040242567Abstract: The present invention relates to the use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension or pulmonary hypertension.Type: ApplicationFiled: April 15, 2004Publication date: December 2, 2004Inventors: Sylvie Cosnier-Pucheu, Dino Nisato, Alain Roccon
-
Publication number: 20040167108Abstract: Combinations of an ACE inhibitor, an aldosterone antagonist, and a loop diuretic are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril, enalapril or lisinopril co-administered with spironolactone. This co-therapy would be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or prevent the progression of congestive heart failure in patients with cardiovascular disease.Type: ApplicationFiled: January 8, 2004Publication date: August 26, 2004Applicant: G.D. Searle & Co.Inventors: Alfonzo T. Perez, Debra J. Asner, Richard J. LaChapelle, John C. Alexander, Barbara Roniker
-
Publication number: 20040087578Abstract: A pharmaceutical combination preparation for the treatment of cardiac and cardiovascular disorders, such as hypertension, angina pectoris, cardiac insufficiency and illnesses associated therewith, contains the active substances carvedilol, or a pharmaceutically acceptable salt thereof, and hydrochlorothiazide, or a pharmaceutically acceptable salt thereof, as well as pharmaceutically usual additives.Type: ApplicationFiled: October 24, 2003Publication date: May 6, 2004Inventor: Rudolf Heller
-
Publication number: 20040034016Abstract: A diuretic, e.g., loop diuretic or thiazide, or a sulphylurea is useful in the treatment of DNA viral infections.Type: ApplicationFiled: March 20, 2003Publication date: February 19, 2004Inventors: Ian Stuart Pardoe, Christopher Edward Hartley
-
Publication number: 20040002529Abstract: A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: 1Type: ApplicationFiled: May 20, 2003Publication date: January 1, 2004Applicant: SANKYO COMPANY, LIMITEDInventors: Toshio Sada, Makoto Mizuno
-
Publication number: 20030235583Abstract: Methods and uses for the prevention and intervention of Type 1 diabetes and LADA comprising administration of a modulator of CD3 and a beta cell resting compound.Type: ApplicationFiled: June 11, 2003Publication date: December 25, 2003Inventors: Jeppe Sturis, Birgitte Koch Michelsen
-
Publication number: 20030216384Abstract: The present invention relates to a composition for the treatment and/or prevention of hypertension, said composition comprising an synergistic anti-hypertensive combination of a therapeutically effective amount of at least one angiotensin II inhibitor, and a therapeutically effective amount of at least one nitric oxide donor; said composition optionally further comprising a pharmaceutically acceptable carrier, diluent and/or adjuvant.Type: ApplicationFiled: September 25, 2002Publication date: November 20, 2003Applicant: Northern Sydney Area Health ServiceInventor: Gordon Stokes
-
Publication number: 20030083246Abstract: The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.Type: ApplicationFiled: July 2, 2001Publication date: May 1, 2003Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert J. Peach, Jean-Claude Becker
-
Patent number: 6485745Abstract: The present invention is concerned with solid oral dosage forms of comprising a) an active agent selected from valsartan and optionally HCTZ , and b) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.Type: GrantFiled: August 1, 2001Date of Patent: November 26, 2002Assignee: Novartis AGInventors: Robert Frank Wagner, Yoshimitsu Katakuse, Takashi Taike, Fujiki Yamato, Manfred Kohlmeyer
-
Patent number: 6436437Abstract: This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmicokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic and neurological drugs, agents and compounds, for rapid and efficient introduction of such agents across the blood-brain barrier.Type: GrantFiled: February 15, 2000Date of Patent: August 20, 2002Assignee: Oregon Health and Science UniversityInventors: Milton B. Yatvin, Michael H. B. Stowell, Michael J. Meredith
-
Publication number: 20020091124Abstract: The invention relates to novel indole and heteroindole derivatives of the formula I 1Type: ApplicationFiled: April 27, 2001Publication date: July 11, 2002Inventors: Thomas Beckers, Silke Baasner, Thomas Klenner, Siavosh Mahboobi, Herwig Pongratz, Markus Frieser, Harald Hufsky, Jorg Hockemeyer, Heinz-Herbert Fiebig, Angelika Burger, Frank-D Bohmer
-
Patent number: 6403579Abstract: A pharmaceutical combination preparation for the treatment of cardiac and cardiovascular disorders, such as hypertension, angina pectoris, cardiac insufficiency and illnesses associated therewith, contains the active substances carvedilol, or a pharmaceutically acceptable salt thereof, and hydrochlorothiazide, or a pharmaceutically acceptable salt thereof, as well as pharmaceutically usual additives.Type: GrantFiled: November 23, 1999Date of Patent: June 11, 2002Assignee: Hoffman-La Roche Inc.Inventor: Rudolf Heller
-
Publication number: 20020052367Abstract: A pharmaceutical combination preparation for the treatment of cardiac and cardiovascular disorders, such as hypertension, angina pectoris, cardiac insufficiency and illnesses associated therewith, contains the active substances carvedilol, or a pharmaceutically acceptable salt thereof, and hydrochlorothiazide, or a pharmaceutically acceptable salt thereof, as well as pharmaceutically usual additives.Type: ApplicationFiled: September 5, 2001Publication date: May 2, 2002Inventor: Rudolf Heller
-
Patent number: 6342247Abstract: Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.Type: GrantFiled: October 11, 2000Date of Patent: January 29, 2002Assignee: Sanofi-SynthelaboInventors: Cathy C. Ku, Omar L. Sprockel, Beth A. Lang, Divvakant S. Desai
-
Publication number: 20010044455Abstract: A method of treatment using a compound of Formula I: 1Type: ApplicationFiled: May 23, 2001Publication date: November 22, 2001Applicant: Boehringer Mannheim Pharmaceuticals Corporation-Inventors: Mary Ann Lukas-Laskey, Robert Ruffolo, Neil Howard Shusterman, Gisbert Sponer, Klaus Strein
-
Patent number: 6313112Abstract: The present invention is generally directed to potassium adenosine triphosphate (“KATP”) channel opening compositions. The present invention also relates to the use of KATP channel openers in therapeutic applications. The KATP channel opening compositions of the present invention include diazoxide (7-chloro-3-methyl-2H-1,2,4-benzo-thiadiazine 1,1-dioxide) and aprikalim. According to the present invention, diazoxide and aprikalim can be used independently, or in combination. The present also relates to therapeutic methods for protecting neuronal function utilizing KATP channel openers. Methods of the present invention may be advantageous for protecting neuronal function, prior to medical procedures, after stroke-like events or other events associated with reductions in blood flow, and/or for preserving tissues or organs against cellular injury and death during removal, storage, transplantation or reattachment.Type: GrantFiled: October 20, 2000Date of Patent: November 6, 2001Assignee: Wake Forest UniversityInventor: David W. Busija
-
Patent number: 6294197Abstract: The present invention is concerned with solid dosage forms comprising a) valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.Type: GrantFiled: May 7, 1999Date of Patent: September 25, 2001Assignee: Novartis AGInventors: Robert Frank Wagner, Yoshimitsu Katakuse, Takashi Taike, Fujiki Yamato, Manfred Kohlmeyer
-
Patent number: 6245787Abstract: Methods of treating congestive heart failure in a mammal, especially a human, by co-administration of (1) amlodipine, a pharmaceutically acceptable salt of amlodipine; (2) an ACE inhibitor; and optionally (3) a diuretic and/or (4) digoxin.Type: GrantFiled: February 26, 1998Date of Patent: June 12, 2001Assignee: Pfizer Inc.Inventors: Anne B. Cropp, Allen R. Kraska
-
Patent number: RE39300Abstract: Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.Type: GrantFiled: June 15, 2001Date of Patent: September 19, 2006Assignee: Virginia Commonwealth University Medical College of VirginiaInventors: David J. Mayer, Jianren Mao
-
Patent number: RE40000Abstract: A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction wType: GrantFiled: November 25, 2003Date of Patent: January 8, 2008Assignee: SB Pharmco Puerto Rico Inc.Inventors: Mary Ann Lukas-Laskey, Robert Ruffolo, Jr., Neil Howard Shusterman, Gisbert Sponer, Klaus Strein